Healthcare Industry News:  radiosurgery 

Devices Oncology Personnel

 News Release - May 17, 2022

Accuray Appoints Sandeep Chalke as SVP, Chief Commercial Officer

SUNNYVALE, Calif., May 17, 2022 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (NASDAQ: ARAY) announced today that Sandeep Chalke has joined the company as senior vice president, chief commercial officer effective May 16, 2022. Mr. Chalke will have responsibility for the global commercial, product development, R&D and engineering functions for the company reporting to Accuray president and forthcoming CEO, Suzanne Winter.

Mr. Chalke brings more than 25 years of medical device expertise in commercialization, business development and operations, spanning multiple healthcare industry segments including interventional catheterization systems, diagnostic x-ray, C-arm linear accelerators, anesthesia and respiratory care, advanced wound dressing & diabetes. Most recently, he served as president, Asia-Pacific and Latin America regions at Vyaire Medical, a global respiratory care manufacturer, where he had full P&L responsibility along with oversight of select manufacturing sites. Prior to Vyaire, Mr. Chalke held various global leadership positions at Medtronic, Acelity, Inc. and GE Healthcare, where he led the development of new products and service solutions, established new markets and partnerships with government organizations and private payors to drive revenue growth, margin expansion and technology leadership.

"Sandeep has a track record of delivering commercial growth, advancing global market expansion and building world class customer support organizations. We welcome Sandeep to the Accuray team and look forward to his leadership in driving customer centricity throughout our organization and accelerating our commercialization strategy across global markets," said Suzanne Winter, president of Accuray. "I believe Sandeep's multi-sector medtech industry background will enable him to bring a unique perspective to our business that will help the Accuray team deliver on our corporate objectives."

"I am thrilled to join the Accuray team and have been impressed with the organization's passion and commitment to creating a better future for cancer patients through technology innovation and advancing radiation therapy care. I look forward to leading the company's efforts to drive patient access, gain market share and create long term value for all stakeholders," said Sandeep Chalke.

About Accuray

Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit or follow us on Facebook, LinkedIn, Twitter, and YouTube.

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, expectations related to value creation, revenue growth, and margin expansion and expectations regarding the transition of leadership, including related to the company's plans, goals and objectives. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the COVID-19 pandemic on the operations of the company and those of its customers and suppliers; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products, including new product and software offerings; the company's ability to develop new products or enhance existing products to meet customers' needs and compete favorably in the market, the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to effectively manage its growth; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on April 29, 2022 and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Source: Accuray

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.